WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.


L02 ENDOCRINE THERAPY

Estrogens and progestogens used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system.

The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).


L02A HORMONES AND RELATED AGENTS

Antigrowth hormones like somatostatin and octreotide, which are also used in the treatment of neoplastic diseases, are classified in H01CB.


L02AA Estrogens

Polyestradiol and combined products, which contain polyestradiol and local anestethics, are classified at the plain level L02AA02 - polyestradiol phosphate.


    ATC code  Name  DDD  U Adm.R Note
    L02AA04 fosfestrol 0.25 
    0.25 

List of abbreviations

Last updated: 2024-01-26